Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · NECTAR LIFESCIENCES LTD. · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
NECTAR LIFESCIENCES LTD.
NSE: NECLIFE · BSE: 532649

NECTAR LIFESCIENCES LTD.

StateQ1 FY27 filed
Last close · 20 Sept 202610.86
Market cap0.2k cr
TTM P/E · P/B · EV/EBITDA · 0.36 · 18.7

NECTAR LIFESCIENCES LTD. is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.

What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.

Exhibit 1: Financial summary, FY22FY26 (all audited; no estimate years)

₹ crore · consolidatedFY22FY23FY24FY25FY26
Revenue1,6691,5251,6861,6730
EBITDA (ex other income)15954153(26)(61)
margin %9.53.59.1(1.6)
Owners' profit000(114)(293)
EPS, as reported (₹)1.12(1.08)0.22(5.07)(13.40)
ROE % · ROCE %2.3 · 8.1(2.3) · 2.90.5 · 8.7(11.9) · (8.5)(50.3) · (8.7)
Debt / equity (x)0.790.710.590.610.00
Cash from operations95134225169(349)
Capex(25)(30)(29)(44)(12)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · NECTAR LIFESCIENCES LTD. · 22 September 2026Page 2 of 3

Exhibit 2: Quarterly performance, last 8 quarters

₹ croreQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue4284554312815000
Profit before tax913(188)(97)(1)57(57)(25)
Net profit68(130)(63)(176)14(68)(15)
EPS (₹)0.250.35(5.80)(2.82)(7.84)0.64(3.38)(0.79)
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · NECTAR LIFESCIENCES LTD. · 22 September 2026Page 3 of 3

Exhibit 3: Filings of the last 90 days, with the measured price reaction

Date · filingCategoryImportance1-day %5-day %
19 Sept 2026 · Revised 31st AGM proceedings filed after cut-off date errorboard shareholder meetingslow
18 Sept 2026 · AGM 2026 voting results: all 5 resolutions passedcomplianceminimal
18 Sept 2026 · Proceedings of 31st AGM held on September 18, 2026board shareholder meetingslow
22 Aug 2026 · Nectar Lifesciences sets Sep 18, 2026 for 31st AGM; e-voting Sep 15-17board shareholder meetingslow
21 Aug 2026 · 31st AGM notice published; e-voting Sep 15-17, 2026complianceminimal
20 Aug 2026 · Nectar Lifesciences 31st AGM notice, September 18, 2026 via video conferencingboard shareholder meetingslow
20 Aug 2026 · Notice of 31st AGM on September 18, 2026 via video conferencingcomplianceminimal
14 Aug 2026 · Book closure set for 31st AGM, record date Sep 11 2026board shareholder meetingslow
14 Aug 2026 · Nectar Lifesciences posts Q1 FY27 loss of Rs 13.46 cr, appoints directormanagement changesmedium
14 Aug 2026 · Nectar Lifesciences Q1 FY27 results: net loss of Rs 13.14 cr, board changesresultshigh
Source: exchange announcements; reaction = close-to-close from the filing's session.

How to read this document

Where a broker report showsThis document showsWhy
A rating (BUY / ADD / REDUCE / SELL)A state: the latest filed quarter and the measured reactionsan event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upsideThe current price and the multiples against the groupa target is a forecast; a multiple is a measurement
Estimate years marked EMore audited years; no estimatesMarketPing publishes no forecasts — your own model lives on the Models page

Sources, method and disclosures

This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.

Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in